WIRED Dec 29 25
Psychedelic Therapy Crashed and Burned. MAHA Might Bring It Back:
Abuse allegations and infighting helped kill a campaign to legalize MDMA for medical use ...
wired.com/story/psychedelic-therapy-mdma-maha/
Story Details
| Last Updated | |
| Total Articles | 6 |
Main Topics
Multidisciplinary Association for Psychedelic Studies
#multidisciplinary-association-for-psychedelic-studies
American organization working to raise awareness and understanding of psychedelic substances
agency of the US Department of Health and Human Services
Similar to This
Previous
Israeli study of psychedelic use for treating PTSD could expand trauma care: Israelis are grappling with rising trauma symptoms in the wake of prolonged war ...
ynetnews.com/health_science/article/rkvgu6yezl
How Elon Musk’s billionaire Doge lieutenant took over the US’s biggest MDMA company
theguardian.com/technology/ng-interactive/2025/aug/28/elon-musk-antonio-gracias-mdma-psychedelics-company
Top Elon Musk Acolyte Running Large MDMA Empire: A close confidante of Elon Musk's who once worked at his DOGE agency is now in control of a pharma company ...
futurism.com/neoscope/elon-musk-acolyte-mdma
This NYT Story Blasting Leftists Is Wildly Misleading and Dangerous. Why Did They Publish It?
slate.com/technology/2025/03/rfk-jr-mdma-psychedelic-therapy-new-york-times-lykos-fda-approval.html
How a Leftist Activist Group Helped Torpedo a Psychedelic Therapy: The fallout from the F.D.A.’s rejection of MDMA-assisted treatment for PTSD worries ...
nytimes.com/2025/02/04/health/fda-mdma-psychedelic-therapy-psymposia.html
FDA rejects MDMA in combination with therapy as treatment for PTSD: A panel of independent advisers for the FDA recommended against approval.
abcnews.go.com/Health/fda-rejects-mdma-combination-therapy-treatment-ptsd/story
Key FactsFDA rejects MDMA therapy for PTSD
Aug 10, 2024 · Reading time: ~45 sec.
Summary created with AI assistance · Source: apnews.com
Summary created with AI assistance · Source: apnews.com
- On August 9, the FDA told Lykos Therapeutics the drug could not be approved based on data submitted to date.
- The agency requested an additional late-stage study, and Lykos said it plans to seek reconsideration.
- Government advisers overwhelmingly opposed MDMA in June after reviewing study data, methods and potential risks.
- FDA staff said the vast majority of patients guessed their treatment; separate allegations of research misconduct also emerged against researchers.
The FDA request for another study is deeply disappointing,— Amy Emerson, CEO of Lykos Therapeutics, said Friday in a statement.
Next